NeuClone to Initiate P-I Clinical Study of Stelara (ustekinumab, biosimilar) in Australia

 NeuClone to Initiate P-I Clinical Study of Stelara (ustekinumab, biosimilar) in Australia

NeuClone to Initiate P-I Clinical Study of Stelara (ustekinumab, biosimilar) in Australia

Shots:

  • Neuclone plans for the onset of P-I clinical study for NeuLara, a Stelara’s biosimilar evaluating NeuLara vs the US & EU score of Stelara in healthy candidates in Australia under CTN scheme of TGA in H2’19
  • NeuLara is developed utilizing NeuMAX technology & Right from the Start development approach, analytically tested with X-ray crystallography for the confirmation of the identical structure b/w NeuLara and Stelara
  • J&J’s Stelara (ustekinumab) is a mAb targeting IL-12 and IL-23, approved for moderate to severe plaque psoriasis in adults and children aged ≥12yrs and has generated $5.2B revenue in 2018. NeuLara X-ray Crystallography is technique allowing 3-D imagining of complex molecules

Click here to read full press release/ article | Ref: PRNewsWire | Image: NeuClone

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post